Evaluating the EU Paediatric Regulation
This article was originally published in SRA
Executive Summary
Nearly a year has elapsed since companies seeking marketing authorisations in the European Union were required to begin submitting paediatric investigation plans or requests for waivers/deferrals under the Paediatric Regulation1, and nearly two years have passed since the European Medicines Agency’s Paediatric Committee (PDCO) held its first meeting. In light of the timing, RAJ Pharma decided it was apt to assess the paediatric programme’s success and to learn more about developments that are in the pipeline.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.